

# Ipca Laboratories Limited

Regd. Office : 48, Kandivli Industrial Estate, Kandivli (W), Mumbai-400 067.

## UNAUDITED FINANCIAL RESULTS

(Rs. Crores)

Particulars	Quarter Ended		Year Ended
	30.06.2011	30.06.2010	31.03.2011 (Audited)
<b>Gross Sales</b>	<b>542.45</b>	<b>427.07</b>	<b>1920.94</b>
Less : Excise Duty and Sales Tax	16.12	12.57	55.02
<b>Net Sales</b>	<b>526.33</b>	<b>414.50</b>	<b>1865.92</b>
Other Operating Income	3.57	3.48	15.18
<b>Total Income</b>	<b>529.90</b>	<b>417.98</b>	<b>1881.10</b>
<b>Expenditure</b>			
a) (Increase)/decrease in stock in trade and work in progress	(11.34)	(13.57)	(48.69)
b) Materials consumption	198.99	165.30	721.62
c) Purchase of traded goods	22.72	23.09	94.64
d) Employees Cost	83.57	65.75	261.59
e) Depreciation / Amortisation	15.41	12.88	55.43
f) Manufacturing and other expenditure	140.78	106.18	473.45
<b>Total Expenditure</b>	<b>450.13</b>	<b>359.63</b>	<b>1558.04</b>
<b>Profit from operations before Other Income, Foreign Exchange translations (gain)/loss, Interest &amp; Tax</b>	<b>79.77</b>	<b>58.35</b>	<b>323.06</b>
Other Income	2.65	2.51	8.44
<b>Profit before Foreign Exchange translations (gain)/loss, Interest &amp; Tax</b>	<b>82.42</b>	<b>60.86</b>	<b>331.50</b>
Foreign Exchange translations (gain) / loss	(9.10)	2.93	(43.34)
Financial cost	8.33	6.79	31.14
<b>Profit before tax</b>	<b>83.19</b>	<b>51.14</b>	<b>343.70</b>
Tax Expense (including Deferred Tax and short/(excess) provision of Tax for earlier years)	21.52	12.30	78.37
<b>Net Profit after tax (before exceptional item)</b>	<b>61.67</b>	<b>38.84</b>	<b>265.33</b>
Exceptional item:			
Provision for investment in subsidiaries	-	-	9.96
<b>Net Profit (after exceptional item)</b>	<b>61.67</b>	<b>38.84</b>	<b>255.37</b>
Paid-up equity share capital (Face value of Rs. 2/- each)	25.14	25.04	25.14
Reserves excluding revaluation reserve	-	-	1028.72
<b>Earnings per share (Rs.) (before exceptional item)</b>			
Basic	<b>4.91</b>	<b>3.10</b>	<b>21.16</b>
Diluted	<b>4.90</b>	<b>3.09</b>	<b>21.15</b>
<b>Earnings per share (Rs.) (after exceptional item)</b>			
Basic	<b>4.91</b>	<b>3.10</b>	<b>20.36</b>
Diluted	<b>4.90</b>	<b>3.09</b>	<b>20.35</b>
Aggregate of public shareholding			
- Number of shares	67820715	67345965	67820715
- Percentage of shareholding	53.95%	53.78%	53.95%
Promoters and Promoter group shareholding			
a) Pledged / Encumbered			
- Number of Shares	7747900	13970000	7841082
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	13.38%	24.14%	13.55%
- Percentage of Shares (as a % of the total share capital of the Company)	6.16%	11.16%	6.24%
b) Non - encumbered			
- Number of Shares	50137790	43911690	50044608
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	86.62%	75.86%	86.45%
- Percentage of Shares (as a % of the total share capital of the Company)	39.89%	35.06%	39.81%


### Notes:

- The above unaudited financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on July 28, 2011.
- The Auditors of the Company have carried out the limited review of the above unaudited financial results in terms of clause 41 of the Listing Agreement.
- During the quarter, the Company has subscribed to the capital of a newly incorporated subsidiary company Prayas Bio Lifescience Limited which will be engaged in Research and Development of Biotech/Recombinant DNA Technology products.
- The entire operations of the Company relate to only one segment viz. 'Pharmaceuticals'.
- Previous year's figures have been regrouped, wherever necessary.
- During the quarter, 24 investor grievances were received and all were disposed off. No grievances were pending either at the beginning or at the end of the quarter.

Place : Mumbai  
Date : July 28, 2011



By Order of the Board  
For Ipca Laboratories Limited

  
Premchand Godha  
Managing Director